Kilitch Drugs (India) (NSE:KILITCH) Construction In Progress: ₹1,400 Mil (As of Mar. 2026)


NSE:KILITCH Kilitch Drugs (India) Ltd NSE:KILITCH
84 GF Score
Price ₹194.73
GF Value ₹232.78
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Kilitch Drugs (India) Construction In Progress?

Kilitch Drugs (India) NSE:KILITCH +4.50% 84 Construction In Progress is ₹1,400 Mil as of Mar. 2026. GuruFocus rates NSE:KILITCH with a GF Score™ of 84/100 and a GF Value™ of ₹232.78 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Kilitch Drugs (India)'s quarterly construction in progress declined from Sep. 2025 (₹979 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹1,400 Mil).

Kilitch Drugs (India)'s annual construction in progress increased from Mar. 2024 (₹60 Mil) to Mar. 2025 (₹473 Mil) and increased from Mar. 2025 (₹473 Mil) to Mar. 2026 (₹1,400 Mil).

Kilitch Drugs (India) Construction In Progress Historical Data

* Premium members only.

The historical data trend for Kilitch Drugs (India)'s Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kilitch Drugs (India) Construction In Progress Chart

Kilitch Drugs (India) Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.61 36.19 59.65 472.95 1,400.19

Kilitch Drugs (India) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 472.95 0.00 978.79 0.00 1,400.19
NSE:KILITCH
84GF Score
Kilitch Drugs (India) Ltd NSE:KILITCH
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kilitch Drugs (India) Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹1,400 Mil mean?
Kilitch Drugs (India) (NSE:KILITCH) has a Construction In Progress of ₹1,400 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Kilitch Drugs (India) and its competitors.
Is Kilitch Drugs (India)'s Construction In Progress too high?
Kilitch Drugs (India)'s current Construction In Progress is ₹1,400 Mil. Overall, Kilitch Drugs (India) has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s Construction In Progress compare to ZTS and UTHR?
Kilitch Drugs (India)'s Construction In Progress of ₹1,400 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Kilitch Drugs (India) and its competitors. Kilitch Drugs (India)'s current Construction In Progress is ₹1,400 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹232.78, compared to a current price of ₹194.73 — trading 16.3% below its estimated fair value. The current Construction In Progress is ₹1,400 Mil. Kilitch Drugs (India)'s overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current Construction In Progress is ₹1,400 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?

Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued. The current stock price of ₹194.73 is trading 16.3% below its estimated GF Value™ of ₹232.78. GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.

Key valuation signals for NSE:KILITCH:

  • Construction In Progress: ₹1,400 Mil
  • GF Value™: ₹232.78 vs. price of ₹194.73 (16.3% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kilitch Drugs (India) Business Description

Other Exchanges 524500:India
Address Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
84GF Score

Get the complete analysis for NSE:KILITCH

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹194.73
Price
₹232.78
GF Value